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Summary Using an RNAse protection assay, expression of messenger RNA for isoforms of TGF-P was
determined in a series of breast cancers. Of 50 tumours, 45 (90%) expressed TGF-P, mRNA, 39 (78%)
expressed TGF-P2, and 47 (94%) expressed TGF-P3. Patterns of expression varied between different tumours:
37 (74%) cancers expressed all three TGF-P isoforms, ten (20%) expressed only two isoforms and two
expressed TGF-P, alone. One sample showed no evidence ofTGF-P mRNA expression. Although most breast
cancers expressed mRNA for at least one isoform of TGF-P, there were differences in patterns of mRNA
expression between individual tumours. The relatively small number of tumours examined precluded detailed
analysis between expression and other clinical parameters, but a significant association was identified between
one aspect of isoform expression and lymph node status, in that the majority of tumours expressing all three
isoforms were associated with lymph node involvement, whereas tumours without one or more isoform were
usually lymph node negative (P = 0.025 by Fisher's exact test).
The transforming growth factor betas (TGF-ps) are a family
of polypeptides which have important regulatory roles in a
diverse series of processes including angiogenesis, embryo-
genesis, inflammation and immunosuppression (Roberts et
al., 1987, 1990; Roberts & Sporn, 1989) within both normal
and transformed cells and tissues (Massague, 1987). There is
evidence of altered expression ofTGF-ps in cancers (Travers
et al., 1988; Barrett-Lee et al., 1990), and certain tumours
may both synthesise and respond to TGF-ps (Hsuan, 1989).
It has thus been suggested that the growth of these tumours
may be influenced by autocrine secretion ofTGF-P (Roberts
et al., 1988), and that dysregulation of TGF-P secretion may
occur in certain cancers (Lippman et al., 1987; Knabbe et al.,
1991). It may also be relevant that the anti-oestrogen tamox-
ifen, which inhibits the growth of hormone-dependent
tumours, can modify TGF-P expression in breast tissues
(Salomon et al., 1989; Sporn et al., 1990; Mizukami et al.,
1991; McCune et al., 1992).
While most studies in TGF-P in breast cancer have been
restricted to analysis ofTGF-p1, it is evident from work with
cell lines that breast cancers may express other isoforms
(Arrick et al., 1990) that have biological activity (Zugmaier et
al., 1989; Colletta et al., 1990), and that patterns of expres-
sion vary between cell lines (Arrick et al., 1990). The aim of
this study was to examine the expression of mRNA for the
three different isoforms ofTGF-P in a series of human breast
cancers.
Materials and methods
Tissues
Samples were obtained from 50 patients (age range 41-91
years) presenting with histologically proven primary breast
cancer to the Edinburgh Breast Unit. Fresh tumour tissue
was obtained from wedge biopsy, wide excision or mastec-
tomy specimens, snap frozen within 30 min of removal and
stored in liquid nitrogen for later RNA extraction.
The oestrogen receptor status of the tumours was deter-
mined as described previously by Hawkins et al. (1975, 1987)
with a value of >20 fmol per mg of protein cytosol being
regarded as positive (Anderson et al., 1989). Tumour stage
was determined on clinical examination, and tumour type
and lymph node status were obtained from the pathology
reports. Tumour stage ranged from TI to T4 (1, 28, 6 and 13
respectively) and tumours were histologically classified as 37
invasive ductal carcinomas of no special type, six invasive
lobular carcinomas and seven of various special types.
Lymph node involvement was determined by histological
examination of axillary node sample or clearance specimens.
Of the patients, 17 had been treated with tamoxifen and one
with goserelin, and the remainder were untreated.
RNA extraction
Total RNA was extracted using a modification of the method
of Auffrey and Rougeon (1980). Frozen tumour tissue
(minimum weight 0.4 g) was dismembranated in liquid nitro-
gen, suspended in 3 M lithium chloride-6 M urea (6 ml),
sonicated and nucleic acids precipitated overnight at 4C.
Total RNA was recovered by centrifugation (15,000g), and
resuspended in 10 mM Tris/0.5% SDS (6 ml) containing pro-
teinase K (50 ig ml-') and incubated at 37C for 20 min.
Protein was removed using 100% phenol (pre-equilibrated
with 0.1 M Tris, pH 7.4) followed by phenol-chloroform-
isoamyl alcohol (25:24:1 v/v/v) and 100% chloroform by
centrifugation, with the aqueous phase recovered on each
occasion. The RNA was precipitated overnight at - 80°C in
lithium chloride (300 ,l, 8 M) and absolute alcohol (2.5
volumes) then recovered by centrifugation (4,000 g, 4°C for
45 min) and resuspended in diethyl pyrocarbonate-treated
water. RNA content and purity were assessed by spectro-
photometry at 260 nm and 280 nm. RNA aliquots (20;Lg)
were stored at - 80C or in liquid nitrogen until assayed.
Synthesis ofriboprobes
Specific probes were prepared as described by Bartlett et al.
(1992) using a Gemini II system (Promega, UK), and full-
length transcripts were isolated by polyacrylamide electro-
phoresis. The probe bands were eluted from the gel and
resuspended in hybridisation buffer for use in the RNAse
protection assay.
RNAse protection assay
This was carried out as described in Bartlett et al. (1992).
Owing to the similarity in sizes of TGF-P, and TGF-P2, and
ofTGF-P3 and actin, these pairs ofprobes were not added to
the same sample aliquot for hybridisation. For those samples
to which TGF-P3 was added, another aliquot containing the
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full transcript for actin was analysed in parallel on a separate
gel, thus ensuring the integrity of the RNA extract. Sample-
probe hybrids remaining after digestion with RNAse were
denatured and separated by gel electrophoresis.
Sample scoring and statistics
Sample RNA extracts were considered positive for each
TGF-P isoform when a band of the appropriate length (full-
length transcript) was observed in the presence of a positive
transcript for control actin. Absence of such a band was
considered a negative result. Expression of each TGF-P
mRNA isoform and expression patterns were related to
clinical, biochemical and histological parameters and associa-
tions were examined using Fisher's exact test.
Results
Representative autoradiographs from RNAse protection
assays for each of the isoforms of TGF-P are shown in
Figure 1. In the autoradiographs probe standards are visible
as bands migrating slightly above the level of the correspon-
ding sample bands. This is due to the continued presence of
polylinked ends on the probe standards. tRNA controls were
run on each gel and are negative for all probes. Sample RNA
extracts were examined for bands corresponding to the TGF-
P probe added. Of the 50 tumours studied, 45 showed expres-
sion of mRNA for TGF-pl, 39 expressed mRNA for TGF-P2,
and 47 expressed mRNA for TGF-133.
Despite high rates of expression for all three isoforms,
different patterns of expression were evident in individual
tumours (Table I). The majority of tumours (37) expressed
all isoforms ofTGF-B, ten expressed only two isoforms (eight
expressing TGF-P1 AND TGF-P3; two expressing TGF-P2
and TGF-P3) and two expressed TGF-P1 alone. One tumour
did not appear to express mRNA for any isoform, although
a positive signal was obtained for control actin.
Oestrogen receptor (ER) status was measured in 48 of the
50 tumours, of which 30 were ER positive and 18 ER
negative. Correlations between expression of individual
mRNA isoforms and oestrogen receptor status are shown in
Table II. None of the relationships was statistically
significant, although tumours not expressing either TGF-132
or -A3 mRNA tended to be ER positive.
There were 21 histological lymph node (LN)-positive and
20 lymph node-negative tumours; in another nine tumours
the axillary node status was not determined histologically.
The relationships between lymph node status and TGF-P
isoform expression are shown in Table III. These again were
non-significant, although showing a trend for tumours with-
out expression of individual TGF-P isoforms to be LN
negative. The data were also analysed as a comparison of
tumours which express mRNA for all three TGF-P isoforms
vs those that do not (Table IV). This identified a significant
relationship, with the majority (57%) of tumours expressing
all three isoforms being associated with lymph node involve-
ment, whereas most tumours (82%) from patients whose
tumours were without one or more isoforms were more likely
to be LN negative.
There were no correlations evident between TGF-P expres-
sion patterns and treatment status.
Discussion
The effects of TGF-Ps on tumour growth are controversial,
in that, while they may directly inhibit proliferation of
epithelial cancer cells (Lippman et al., 1987; Knabbe et al.,
1991), TGF-ps may also promote tumour growth by their
angiogenic and immunosuppressive properties (Roberts et al.,
1988; Salomon et al., 1989) and effects on the extracellular
matrix.
In the breast, several studies which have compared levels
of TGF-P mRNA in normal, benign and malignant tissue
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Figure 1 TGF-13 mRNA expression in human breast cancer.
Representative autoradiographs showing expression of the three
human TGF-13 mRNA isoforms as determined by RNAse protec-
tion assay.
Table I Summary ofTGF-P mRNA expression patterns
Three isoforms
TGF-P, + P2 + P3 37 (74%)
Two isoforms
TGF-P, + P3 8 (16%)
TGF-p2 + P3 2 (4%)
One isoform
TGF-pi 2 (4%)
No isoforms
y-Actin 1 (2%)
Total samples 50 (100%)
have suggested that values may be higher in malignant than
non-malignant tissue (Travers et al., 1988; Barrett-Lee et al.,
1990). However, these investigations did not distinguish
between isoforms of TGF-P, although all three human TGF-
13 mRNA isoforms have been detected in breast cancer cell1008 J. MACCALLUM et al.
Table II Expression ofTGF-P mRNA in oestrogen receptor-positive
and -negative breast cancers
Oestrogen receptor
TGF-P, + 28 17 P=1.66
- ~~~2 1
TGF-32 + 21 16 P=0.63
~~~9 2
TGF-P3 27 18 P = 0.65
Table III Expression ofTGF-PmRNA in tumours frompatients with
and without lymph node involvement
Lymph node involvement
TGF-P, + 21 17 P=0.28 - ~~~0 3
TGF-P2 - 19 13 P = 0.25
TGF-P3 21 18 P = 0.46
Table IV Lymph node involvement in patients with tumours
expressing three or fewer than three TGF-P mRNA isoforms
Lymph node involvement
+~
Expression of three 11 19
TGF-P mRNAs P = 0.025
Expression of two or 9 2
fewer TGF-P mRNAs
lines (Arrick et al., 1990; Jeng & Jordan, 1991; Arteaga &
Coffey, 1992). Expression of TGF-P in breast cancer at the
level of the mRNA (Thompson et al., 1990, 1991; Delvenne
et al., 1992; Dalal et al., 1993) has been reported, but to our
knowledge the present investigation is the first in which all
three human TGF-P mRNA isoforms have been examined
systematically in a series of human breast cancers.
It is of interest that high rates of expression for all
isoforms of mRNA were observed, and that few tumours
failed to express TGF-P1 and TGF-P3 mRNA. A further
novel observation is that the pattern of isoform expression
differed between individual tumours, and it was possible to
identify tumours expressing one, two or three isoforms.
Nevertheless, there appeared to be some hierachical order
within the expression patterns. While the majority of
tumours expressed all three isoforms of TGF-P, amongst
those displaying only two isoforms, TGF-P3 mRNA was
always present and the combination of TGF-P, and TGF-P2
was not seen. In addition, in the two tumours expressing only
one isoform, this was TGF-p1. The biological significance of
this differential expression remains to be determined.
More detailed analysis of the present results uncovered a
statistically significant correlation which indicated that the
majority of tumours expressing all three isoforms of TGF-P
were derived from patients who had lymph node metastases,
whereas tumours without one or more isoform tended to be
LN negative. The underlying nature of this association is
undefined. It may be that more aggressive tumours have a
tendency coincidentally to express more forms and types of
growth factor, or increased TGF-P expression may be
associated with the metastatic phenotype. In this respect it
ought to be emphasised that these findings are not based on
consistent non-expression of a particular isoform. While
isoforms of TGF-P may have overlapping biological activity,
receptor studies suggest the existence of cell types that
preferentially or specifically bind to one of the TGF-P
isoforms (Roberts et al., 1988), thus cell responses may be
unique to one of the receptor subtypes (Colletta, 1990).
The present results are not compatible with those previously
reported by Barrett-Lee et al. (1990), which suggest that
TGF-P3 mRNA expression is associated with absence of
lymph node metastases. In the present study, the few
tumours that did not apparently express mRNA for TGF-,B
were usually associated with the absence of lymph node
involvement. However, it may be pertinent that, whereas
Barrett-Lee et al. (1990) attempted quantification of mRNA,
our study is based simply upon a qualitative assessment.
Equally, there is considerable evidence to suggest that the
quantitative levels of mRNA for TGF-ps do not closely
correlate with protein expression (Kehrl et al., 1986; Assoian
et al., 1987; Ikeda et al., 1987; Kim et al., 1992) and that, in
these circumstances, qualitative association of mRNA expres-
sion may be more informative. Our observations would,
however, support those reports which suggest a role for
TGF-P in mammary cancer metastasis (Welch et al., 1990;
Gorsch et al., 1993) in which immunohistochemical staining
for TGF-B3 (but not TGF-P2 and P3) was associated with rate
of disease progression (Gorsch et al., 1992). Similarly,
Walker and Dearing (1992) observed that staining for TGF-
PI protein in primary breast cancers was associated with
metastatic spread to axillary lymph nodes. Further evidence
of a role for TGF-P in tumour spread comes in a recent
immunocytochemical study in which TGF-P1 was localised at
the growing edges of primary cancers (Dalal et al., 1993).
However, further studies, examining a larger number of sam-
ples, analysing both levels of expression and determining the
biological activity of different isoforms of TGF-P are
required before definitive conclusions can be reached regar-
ding the influence of TGF-P expression on tumour progres-
sion.
Although the present study has shown that different TGF-
P mRNA isoforms are expressed by human breast cancers, it
is not possible, using the methodology described, to identify
the cell types responsible for their production. Studies in
lactating and non-lactating bovine mammary tissue suggest
that there is a different spatial distribution for each of the
three TGF-P isoforms (Maier et al., 1991). Immunohisto-
chemistry has been used to identify the site of TGF-P pro-
tein, but the results to date are confusing, with McCune et al.
(1992) suggesting that in a variety of benign and malignant
breast tissues TGF-P tends to be associated intracellularly
within epithelial cells rather than stroma, and Butta et al.
(1992) indicating TGF-P is predominantly seen in the stroma.
Given the potential role of TGF-1 in normal and malignant
breast tissue and the changes in TGF-P which have been
reported after treatment with tamoxifen, it is important to
resolve such anomalies. Our current studies employing
immunohistochemistry and in situ hybridisation aim to
clarify these issues.
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